A Study for Older Adults With Acute Lymphoblastic Leukaemia (UKALL60+)
Acute Lymphoblastic Leukaemia
About this trial
This is an interventional treatment trial for Acute Lymphoblastic Leukaemia
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 60 with Acute Lymphoblastic Leukaemia (ALL) OR ≥ 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
- Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before trial registration))
- Willing and able to give consent
Exclusion Criteria:
- Known HIV infection
- Blast transformation of CML
- Mature B-cell leukaemia i.e. Burkitts disease t(8,14)(q24 ;q32) and variant c-myc translocations e.g. t(2;8)(p12 ;q24), t(8;22)(q24;q11)
- Women who are pregnant or lactating
Sites / Locations
- Erasmus MC
- NHS Lanarkshire - Monklands
- Blackpool Victoria Hopsital
- Royal Bournemouth Hospital
- Bradford Royal Infirmary
- Bristol Haematology and Oncology Centre
- University Hospital of Wales
- Castle Hill Hospital
- Russells Hall Hospital
- Ninewells Hospital
- NHS Lothian - Western General Hospital
- Beatson West of Scotland Cancer Centre
- New Victoria Hospital and Southern General Hospital
- Northwick Park Hospital
- St James' Hospital, Leeds
- Leicester Royal Infirmary
- Royal Liverpool University Hospital
- King's College Hospital NHS Foundation Trust
- St Bartholomew's Hospital
- St George's Hospital
- The Christie Hospital
- James Cook University Hospital
- Churchill Hospital, Oxford
- Derriford Hospital
- Poole General Hospital
- St Helen's & Knowlsey Teaching Hospitals
- Salisbury District Hospital
- Royal Hallamshire Hospital
- Royal MarsdenHospital
- Great Western Hospital
- Musgrove Park
- Torbay Hospital
- Sandwell General Hospital
- Arrowe Park Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
No Intervention
Philadelphia Positive Patients
Philadelphia -ve Patients- Intensive
Philadelphia -ve Patients- Intensive +
Philadelphia -ve Patients- Non Intensive
Registration only
All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.